RecruitingPhase 2NCT06701357
CR-CHOP+X in Previously Untreated DEL
Studying Diffuse large B-cell lymphoma with chronic inflammation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ruijin Hospital
- Intervention
- CR-CHOP+PD1 inhibitor(drug)
- Enrollment
- 49 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06701357 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma with chronic inflammation
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT07538180Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCLSun Yat-sen University
- RECRUITINGNCT07070648Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PETFudan University
- RECRUITINGPHASE1, PHASE2NCT06829771Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT06687772CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06760039Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLSun Yat-sen University
- RECRUITINGPHASE2NCT06664411Pola-ZR2P in Previously Untreated DLBCLNavy General Hospital, Beijing
- RECRUITINGPHASE2NCT06554600A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
See all trials for Diffuse large B-cell lymphoma with chronic inflammation →